Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 14;107(6):1397–1409. doi: 10.3324/haematol.2021.279229

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2022 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 2. — Response rates with isatuximab (Isa) carfilzomib (K) dexamethasone (d) (Isa-Kd) compared with Kd. (A) Patients with renal impairment (RI) (eGFR <60 mL/min/1.73 m²) or (B) without RI (eGFR ≥60 mL/min/1.73 m²), (ITT population). CR: complete response; d: dexamethasone; eGFR: estimated glomerular filtration rate; Isa: isatuximab; ITT: intent to treat; K: carfilzomib; MRD neg: minimal residual disease negativity; ORR: overall response rate; PR: partial response; VGPR: very good partial response. MRD was assessed by next-generation sequencing with a sensitivity level 10^-5.